These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Discovery of CFTR modulators for the treatment of cystic fibrosis. Lopes-Pacheco M; Pedemonte N; Veit G Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators. Fajac I; Sermet-Gaudelus I Curr Opin Pulm Med; 2021 Nov; 27(6):567-574. PubMed ID: 34494979 [TBL] [Abstract][Full Text] [Related]
5. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
6. Patient-derived cell models for personalized medicine approaches in cystic fibrosis. Ramalho AS; Amato F; Gentzsch M J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S32-S38. PubMed ID: 36529661 [TBL] [Abstract][Full Text] [Related]
7. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator. Ong T; Ramsey BW Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186 [TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis: a model system for precision medicine. Martiniano SL; Sagel SD; Zemanick ET Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658 [TBL] [Abstract][Full Text] [Related]
9. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449 [TBL] [Abstract][Full Text] [Related]
10. Translating the genetics of cystic fibrosis to personalized medicine. Corvol H; Thompson KE; Tabary O; le Rouzic P; Guillot L Transl Res; 2016 Feb; 168():40-49. PubMed ID: 25940043 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function. Arora K; Naren AP Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081 [TBL] [Abstract][Full Text] [Related]
16. A new era of personalized medicine for cystic fibrosis - at last! Quon BS; Wilcox PG Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544 [TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. Becq F Drugs; 2010 Feb; 70(3):241-59. PubMed ID: 20166764 [TBL] [Abstract][Full Text] [Related]
18. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies. Ensinck MM; Carlon MS Cells; 2022 Jun; 11(12):. PubMed ID: 35740997 [TBL] [Abstract][Full Text] [Related]
19. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist. Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995 [TBL] [Abstract][Full Text] [Related]
20. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Mall MA; Mayer-Hamblett N; Rowe SM Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]